ong-term clinical follow up study for subjects who had previously taken the experimental drug GSK2248761

• Conditions: HIV-1 infected adults; MedDRA version: 14.0Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 10021881 - Infections and infestations; Therapeutic area: Diseases [C] - Virus Diseases [C02]

• Registration Number: EUCTR2011-003303-38-DE
• Lead Sponsor: ViiV Healthcare UK Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-08-09
• Last Update Posted: 29 July 2013

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

All subjects who were previously randomized in the Phase 2b studies SGN113399 or SGN113404 and received GSK2248761 will be targeted for enrollment in the study.
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 34
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not applicable.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified